NEJM
Policymakers should consider disbanding the 340B program, a student and a professor at the Stanford University School of Medicine say in the New England Journal of Medicine.

End 340B, Commentary in New England Journal of Medicine Suggests

Policymakers should consider disbanding the 340B program “given its negative reverberations for patients and markets,” a student and a professor at the Stanford University School of Medicine wrote in a commentary in the latest edition of the New England Journal of Medicine.

Groups that represent hospitals enrolled in 340B criticized the article (subscription required). They said abolishing the drug discount program would harm rather than help patients, communities, and health care at large.

Policymakers should consider disbanding the 340B program “given its negative reverberations for patients and markets,” a student and a professor at the Stanford University School of Medicine wrote in a commentary in the latest edition of the New England Journal of Medicine.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Attend Our Upcoming Webinar

×


Learn More

Sign up for our free news summaries and alerts